Everything below concerns investigational status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | Designed to engage three receptor targets |
| Appearance | White to off-white powder | Lyophilized form supplied in sealed vials |
| Solubility | Soluble in water | Dissolves in aqueous buffer systems |
| Storage, solid | -20 °C or below | Desiccated and protected from light |
| Typical analysis | RP-HPLC with mass detection | Purity by peak area, identity by mass |
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
== Genomics == The genome of B. cereus has been characterized and shown to contain over 5 million bp of DNA. Out of these, more than 5500 protein-encoding genes have been identified, of which the top categories of genes with known functions include: metabolic processes, processing of proteins, virulence factors, response to stress, and defense mechanisms. Many of the genes categorized as virulence factors, stress responses, and defense mechanisms encode factors in antibiotic resistance. There are approximately 600 genes which are common in 99% of the taxa of B. cereus sensu lato, which constitutes around 1% of all genes in the pan-genome. Due to the prevalence of horizontal gene transfer among bacteria, the pan-genome of B. cereus is continually expanding. The GC content of its DNA across all strains is approximately 35%. Following exposure to non-lethal acid shock at pH 5.4–5.5, the arginine deiminase gene in B. cereus, arcA, shows substantial up-regulation. This gene is part of the arcABC operon which is induced by low-pH environments in Listeria monocytogenes, and is associated with growth and survival in acidic environments. This suggests that this gene is also important for survival of B. cereus in acidic environments. The activation of virulence factors has been shown to be transcriptionally regulated via quorum-sensing in B. cereus. The activation of many virulence factors secreted is dependent on the activity of the Phospholipase C regulator (PlcR), a transcriptional regulator which is most active at the beginning of the stationary phase of growth.
== External links == Fragmentation patterns in the mass spectra of organic compounds A tutorial in small molecule identification via electrospray ionization-mass spectrometry: The practical art of structural elucidation
During the early 1800s, consumers preserved their food by storing food and ice purchased from ice harvesters in iceboxes. In 1803, Thomas Moore patented a metal-lined butter-storage tub which became the prototype for most iceboxes. These iceboxes were used until nearly 1910 and the technology did not progress. In fact, consumers that used the icebox in 1910 faced the same challenge of a moldy and stinky icebox that consumers had in the early 1800s. General Electric (GE) was one of the first companies to overcome these challenges. In 1911, GE released a household refrigeration unit that was powered by gas. The use of gas eliminated the need for an electric compressor motor and decreased the size of the refrigerator. However, electric companies that were customers of GE did not benefit from a gas-powered unit. Thus, GE invested in developing an electric model. In 1927, GE released the Monitor Top, the first refrigerator to run on electricity. In 1930, Frigidaire, one of GE's main competitors, synthesized Freon. With the invention of synthetic refrigerants based mostly on a chlorofluorocarbon (CFC) chemical, safer refrigerators were possible for home and consumer use. Freon led to the development of smaller, lighter, and cheaper refrigerators. The average price of a refrigerator dropped from $275 to $154 with the synthesis of Freon. This lower price allowed ownership of refrigerators in American households to exceed 50% by 1940.
== Structure == Although achiral, glycerol is prochiral with respect to reactions of one of the two primary alcohols. Thus, in substituted derivatives, the stereospecific numbering labels the molecule with a sn- prefix before the stem name of the molecule.
Coeliac disease (Commonwealth English) or celiac disease (American English) is a chronic autoimmune disease, mainly affecting the small intestine. It is caused by an abnormal immune system response to gluten, a protein found in wheat and other grains such as barley and rye. Coeliac disease causes a wide range of symptoms and complications that can affect multiple organs outside the gastrointestinal tract. The classic form of the disease can affect any age group, but is usually diagnosed in early childhood and causes symptoms of malabsorption such as weight loss, diarrhoea, and stunted growth. Non-classic coeliac disease is more commonly seen in adults, characterised by vague abdominal symptoms and complications in organs outside the gastrointestinal tract, such as bone disease, anaemia, and other consequences of nutritional deficiencies. In people with a genetic predisposition to the condition, eating gluten causes inflammation in the small intestine, damaging its lining and leading to malabsorption. The development of coeliac disease is believed to be influenced by other environmental factors, such as infections. Diagnosis is based on symptoms, blood tests, and biopsies of the small intestine. For people who have already cut gluten from their diet, gluten may need to be reintroduced before testing to ensure an accurate diagnosis. A lack of awareness and the diverse symptoms, which overlap with other disorders, often complicate the diagnosis by leading to a delay in diagnosis.
Sources: en.wikipedia.org
===== Rail transport ===== The government intends to start a new wave of investment in the expansion of the Brazilian railway network, with the strategy being to increase investments in railway lines led by the ministry of transport; within the New PAC, the government intends to invest R$94.2 billion in 35 projects, R$55.1 billion by 2026 and more $39.1 billion in subsequent years, the majority of the investments will be through the private sector. The focus, this time, will be the passenger transport, the newspaper Poder360 found that there are 7 most advanced passenger train projects, stretches averaging 100 km connecting municipalities and metropolitan regions, among these, the longest would be the one that connects Fortaleza with Sobral, in Ceará, a stretch of more than 200 km, the others would be in the states of Maranhão, Bahia, Rio de Janeiro, Paraná, Rio Grande do Sul and the Federal District. Currently, there are only two regular passenger lines: between Vitória and Belo Horizonte, and between São Luís and Parauapebas (PA), both are also used to transport cargo; for the construction of these lines, the government sees it as essential to take advantage of the existing railway infrastructure, aimed at transporting cargo, but which is underutilized or in a precarious state of maintenance.
==== Pain circuitry ==== The outcome of NOP activation on the brain's pain circuitry is site-specific. Within the central nervous system its action can be either similar or opposite to those of opioids depending on their location. In animal models, activation of NOP in the brain stem and higher brain regions has mixed action, resulting in overall anti-opioid activity. NOP activation at the spinal cord and peripheral nervous system results in morphine-comparable analgesia in non-human primates.
The related compound and Amanita species constituent ibotenic acid is a prodrug of muscimol, but also has neurotoxic effects. Muscimol was first isolated from Amanita muscaria and hence was discovered in 1964. It has been limitedly clinically studied as a potential pharmaceutical drug for a number of uses, such as treatment of epilepsy. In addition, analogues and derivatives of muscimol, such as the selective GABAA receptor agonist gaboxadol (THIP; LU-2-030) and the selective GABA reuptake inhibitor tiagabine (Gabitril), have been developed as pharmaceutical drugs. Muscimol and Amanita muscaria mushrooms have rarely been used as recreational drugs historically. By the mid-2020s however, use of these substances, including recreational use for hallucinogenic effects and microdosing for claimed therapeutic benefits, has become increasingly prominent. The most commonly cited therapeutic reason for their use is to improve sleep. Muscimol is not a controlled substance and is unregulated in most of the world, including in most of the United States and Europe.
== Adverse effects == As a diuretic, ethacrynic acid can cause frequent urination, but this usually resolves after taking the drug for a few weeks. Ethacrynic acid can also cause low potassium levels, which may manifest as muscle cramps or weakness. It has also been known to cause reversible or permanent hearing loss (ototoxicity) and liver damage when administered in extremely high dosages. On oral administration, it produces diarrhea; intestinal bleeding may occur at higher doses.
The chloroplasts of plants have a number of biochemical, structural and genetic similarities to cyanobacteria, (commonly but incorrectly known as "blue-green algae") and are thought to be derived from an ancient endosymbiotic relationship between an ancestral eukaryotic cell and a cyanobacterial resident. The algae are a polyphyletic group and are placed in various divisions, some more closely related to plants than others. There are many differences between them in features such as cell wall composition, biochemistry, pigmentation, chloroplast structure and nutrient reserves. The algal division Charophyta, sister to the green algal division Chlorophyta, is considered to contain the ancestor of true plants. The Charophyte class Charophyceae and the land plant sub-kingdom Embryophyta together form the monophyletic group or clade Streptophytina. Nonvascular land plants are embryophytes that lack the vascular tissues xylem and phloem. They include mosses, liverworts and hornworts. Pteridophytic vascular plants with true xylem and phloem that reproduced by spores germinating into free-living gametophytes evolved during the Silurian period and diversified into several lineages during the late Silurian and early Devonian. Representatives of the lycopods have survived to the present day. By the end of the Devonian period, several groups, including the lycopods, sphenophylls and progymnosperms, had independently evolved "megaspory" – their spores were of two distinct sizes, larger megaspores and smaller microspores.
Sources: en.wikipedia.org
=== Risk of forgoing conventional medical care === As with other alternative medicines, unethical or naïve practitioners may induce patients to exhaust financial resources by pursuing ineffective treatment. Professional ethics codes set by accrediting organizations such as the National Certification Commission for Acupuncture and Oriental Medicine require practitioners to make "timely referrals to other health care professionals as may be appropriate." Stephen Barrett states that there is a "risk that an acupuncturist whose approach to diagnosis is not based on scientific concepts will fail to diagnose a dangerous condition".
=== EC 1.3.1 With NAD+ or NADP+ as acceptor === EC 1.3.1.1: dihydrouracil dehydrogenase (NAD+) EC 1.3.1.2: dihydropyrimidine dehydrogenase (NADP+) EC 1.3.1.3: Δ4-3-oxosteroid 5β-reductase EC 1.3.1.4: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.5: cucurbitacin Δ23-reductase EC 1.3.1.6: fumarate reductase (NADH) EC 1.3.1.7: meso-tartrate dehydrogenase EC 1.3.1.8: acyl-CoA dehydrogenase (NADP+) EC 1.3.1.9: enoyl-[acyl-carrier-protein] reductase (NADH) EC 1.3.1.10: enoyl-[acyl-carrier-protein] reductase (NADPH, Si-specific) EC 1.3.1.11: 2-coumarate reductase EC 1.3.1.12: prephenate dehydrogenase EC 1.3.1.13: prephenate dehydrogenase (NADP+) EC 1.3.1.14: dihydroorotate dehydrogenase (NAD+) EC 1.3.1.15: dihydroorotate dehydrogenase (NADP+) EC 1.3.1.16: β-nitroacrylate reductase EC 1.3.1.17: 3-methyleneoxindole reductase EC 1.3.1.18: kynurenate-7,8-dihydrodiol dehydrogenase EC 1.3.1.19: cis-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.20: trans-1,2-dihydrobenzene-1,2-diol dehydrogenase EC 1.3.1.21: 7-dehydrocholesterol reductase EC 1.3.1.22: 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.23: Identical to EC 1.3.1.3, Δ4-3-oxosteroid 5β-reductase EC 1.3.1.24: biliverdin reductase EC 1.3.1.25: 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.26: Now EC 1.17.1.8, 4-hydroxy-tetrahydrodipicolinate reductase EC 1.3.1.27: 2-hexadecenal reductase EC 1.3.1.28: 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase EC 1.3.1.29: cis-1,2-dihydro-1,2-dihydroxynaphthalene dehydrogenase EC 1.3.1.30: transferred to EC 1.3.1.22, 3-oxo-5α-steroid 4-dehydrogenase (NADP+) EC 1.3.1.31: 2-enoate reductase EC 1.3.1.32: maleylacetate reductase EC 1.3.1.33: protochlorophyllide reductase EC 1.3.1.34: 2,4 Dienoyl-CoA reductase (NADPH) EC 1.3.1.35: Now EC 1.14.19.22, microsomal oleoyl-lipid 12-desaturase EC 1.3.1.36: geissoschizine dehydrogenase EC 1.3.1.37: cis-2-enoyl-CoA reductase (NADPH) EC 1.3.1.38: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.39: trans-2-enoyl-CoA reductase (NADPH) EC 1.3.1.40: 2-hydroxy-6-oxo-6-phenylhexa-2,4-dienoate reductase EC 1.3.1.41: xanthommatin reductase EC 1.3.1.42: 12-oxophytodienoate reductase EC 1.3.1.43: arogenate dehydrogenase EC 1.3.1.44: trans-2-enoyl-CoA reductase (NAD+) EC 1.3.1.45: 2′-hydroxyisoflavone reductase EC 1.3.1.46: biochanin-A reductase EC 1.3.1.47: α-santonin 1,2-reductase EC 1.3.1.48: 13,14-dehydro-15-oxoprostaglandin 13-reductase EC 1.3.1.49: cis-3,4-dihydrophenanthrene-3,4-diol dehydrogenase EC 1.3.1.50: n Now EC 1.1.1.252 tetrahydroxynaphthalene reductase EC 1.3.1.51: 2′-hydroxydaidzein reductase EC 1.3.1.52: Now EC 1.3.8.5, 2-methyl-branched-chain-enoyl-CoA reductase EC 1.3.1.53: (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.54: precorrin-6A reductase EC 1.3.1.55: identical to EC 1.3.1.25, 1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate dehydrogenase EC 1.3.1.56: cis-2,3-dihydrobiphenyl-2,3-diol dehydrogenase EC 1.3.1.57: phloroglucinol reductase EC 1.3.1.58: 2,3-dihydroxy-2,3-dihydro-p-cumate dehydrogenase EC 1.3.1.59: There is no evidence that the enzyme exists EC 1.3.1.60: dibenzothiophene dihydrodiol dehydrogenase EC 1.3.1.61: identical to EC 1.3.1.53, (3S,4R)-3,4-dihydroxycyclohexa-1,5-diene-1,4-dicarboxylate dehydrogenase EC 1.3.1.62: pimeloyl-CoA dehydrogenase EC 1.3.1.63: Now EC 1.21.1.2, 2,4-dichlorobenzoyl-CoA reductase EC 1.3.1.64: phthalate 4,5-cis-dihydrodiol dehydrogenase EC 1.3.1.65: 5,6-dihydroxy-3-methyl-2-oxo-1,2,5,6-tetrahydroquinoline dehydrogenase EC 1.3.1.66: cis-dihydroethylcatechol dehydrogenase EC 1.3.1.67: cis-1,2-dihydroxy-4-methylcyclohexa-3,5-diene-1-carboxylate dehydrogenase EC 1.3.1.68: 1,2-dihydroxy-6-methylcyclohexa-3,5-dienecarboxylate dehydrogenase EC 1.3.1.69: zeatin reductase EC 1.3.1.70: Δ14-sterol reductase EC 1.3.1.71: Δ24(241)-sterol reductase EC 1.3.1.72: Δ24-sterol reductase EC 1.3.1.73: 1,2-dihydrovomilenine reductase EC 1.3.1.74: 2-alkenal reductase [NAD(P)+] EC 1.3.1.75: 3,8-divinyl protochlorophyllide a 8-vinyl-reductase (NADPH) EC 1.3.1.76: precorrin-2 dehydrogenase EC 1.3.1.77: anthocyanidin reductase [(2R,3R)-flavan-3-ol-forming] EC 1.3.1.78: arogenate dehydrogenase (NADP+) EC 1.3.1.79: arogenate dehydrogenase (NAD(P)+) EC 1.3.1.80: Now classified as EC 1.3.7.12, red chlorophyll catabolite reductase EC 1.3.1.81: (+)-pulegone reductase EC 1.3.1.82: (-)-isopiperitenone reductase EC 1.3.1.83: geranylgeranyl diphosphate reductase EC 1.3.1.84: acrylyl-CoA reductase (NADPH) EC 1.3.1.85: crotonyl-CoA carboxylase/reductase EC 1.3.1.86: crotonyl-CoA reductase EC 1.3.1.87: 3-(cis-5,6-dihydroxycyclohexa-1,3-dien-1-yl)propanoate dehydrogenase EC 1.3.1.88: tRNA-dihydrouridine16/17 synthase (NAD(P)+) EC 1.3.1.89: tRNA-dihydrouridine47 synthase (NAD(P)+) EC 1.3.1.90: tRNA-dihydrouridine20a/20b synthase (NAD(P)+) EC 1.3.1.91: tRNA-dihydrouridine20 synthase (NAD(P)+) EC 1.3.1.92: artemisinic aldehyde Δ11(13)-reductase EC 1.3.1.93: very-long-chain enoyl-CoA reductase EC 1.3.1.94: polyprenol reductase EC 1.3.1.95: acrylyl-CoA reductase (NADH) EC 1.3.1.96: Botryococcus squalene synthase EC 1.3.1.97: botryococcene synthase EC 1.3.1.98: Now known to be catalyzed by two different enzymes, EC 1.3.1.122, (S)-8-oxocitronellyl enol synthase, and EC 5.5.1.34, (+)-cis,trans-nepetalactol synthase EC 1.3.1.100: chanoclavine-I aldehyde reductase EC 1.3.1.101: 2,3-bis-O-geranylgeranyl-sn-glycerol 1-phosphate reductase [NAD(P)H] EC 1.3.1.102: 2-alkenal reductase (NADP+) EC 1.3.1.103: 2-haloacrylate reductase EC 1.3.1.104: enoyl-[acyl-carrier-protein] reductase (NADPH) EC 1.3.1.105: 2-methylene-furan-3-one reductase EC 1.3.1.106: cobalt-precorrin-6A reductase EC 1.3.1.107: sanguinarine reductase EC 1.3.1.108: caffeoyl-CoA reductase EC 1.3.1.109: butanoyl-CoA dehydrogenase complex (NAD+, ferredoxin) EC 1.3.1.110: lactate dehydrogenase (NAD+,ferredoxin) EC 1.3.1.111: geranylgeranyl-bacteriochlorophyllide a reductase EC 1.3.1.112: anthocyanidin reductase [(2S)-flavan-3-ol-forming] EC 1.3.1.113: (4-alkanoyl-5-oxo-2,5-dihydrofuran-3-yl)methyl phosphate reductase EC 1.3.1.114: 3-dehydro-bile acid Δ4,6-reductase EC 1.3.1.115: 3-oxocholoyl-CoA 4-desaturase EC 1.3.1.116: 7β-hydroxy-3-oxochol-24-oyl-CoA 4-desaturase EC 1.3.1.117: hydroxycinnamoyl-CoA reductase EC 1.3.1.118: meromycolic acid enoyl-[acyl-carrier-protein] reductase EC 1.3.1.119: chlorobenzene dihydrodiol dehydrogenase EC 1.3.1.120: cyclohexane-1-carbonyl-CoA reductase NADP+) EC 1.3.1.121: 4-amino-4-deoxyprephenate dehydrogenase EC 1.3.1.122: (S)-8-oxocitronellyl enol synthase EC 1.3.1.123: 8-oxogeranial reductase EC 1.3.1.124: 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]
Methylergometrine is an agonist or antagonist to serotonin, dopamine, and α-adrenergic receptors. Its specific binding and activation pattern on these receptors leads to a highly, if not completely, specific contraction of smooth uterus muscle via serotonin 5-HT2A receptors, while blood vessels are affected to a lesser extent compared to other ergot alkaloids. It has been found to interact with the serotonin 5-HT1A, 5-HT1B, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, and 5-HT7 receptors. Methylergometrine is an agonist of the serotonin 5-HT2B receptor and may be linked to cardiac valvulopathy.
==== Non-nucleic acid-based tests ==== ExaVir™ Load Archived 2011-10-28 at the Wayback Machine Version 3 from Cavidi AB is a largely manual test, which has the European regulatory approval (CE-Mark) for clinical use and is also used for viral load monitoring. Virus-associated reverse transcriptase (RT) activity is measured and can therefore detect all types and subtypes of HIV. The technology does not require sophisticated laboratories.
Naturally occurring rhenium (75Re) is 37.4% 185Re, which is stable (although it is predicted to decay), and 62.6% 187Re, which is unstable but has a very long half-life (4.16×1010 years). Among elements with a known stable isotope, only indium and tellurium similarly occur with a stable isotope in lower abundance than the long-lived radioactive isotope. There are 36 other unstable isotopes recognized, the longest-lived of which are 183Re with a half-life of 70 days, 184Re with a half-life of 35.4 days, 186Re with a half-life of 3.7185 days, 182Re with a half-life of 64.2 hours, and 189Re with a half-life of 24.3 hours. There are also numerous isomers, the longest-lived of which are 186mRe with a half-life of 200,000 years and 184mRe with a half-life of 177.25 days. All others have half-lives less than a day.
Sources: en.wikipedia.org
Solid powder is held frozen at -20 °C or below in a desiccated container. Reconstituted solutions are refrigerated and used within a limited period.
Reversed-phase liquid chromatography separates the peptide from related impurities. Mass spectrometry confirms molecular mass, which supports structural identity.
Repeated freezing and thawing can promote aggregation and precipitation of peptide material. Dividing material into single-use aliquots reduces this risk.
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。